AMB – Quarterly Progress Report (Cumulative)
Quarterly Progress Report (QPR) on age-group wise service deliveries and information on distribution of Iron and Folic Acid (IFA) syrup and tablets- Pink, Blue & Red, Albendazole tablets among the 6 focused age groups. The information is derived on the basis of data updates available from HMIS indicators (Numerator) calculated using the eligible age specific respective denominators for each age group. *The GOI quarter reporting year starts from April and ends in March of the subsequent year (Q1-April to June, Q2-July to September, Q3- October to December and Q4 January to March (of subsequent year)).
Service Delivery in Percentage ( IFA & Deworming )
INDIA
Children 6-59 months
| Year | Upto Q1 | Upto Q2 | Upto Q3 | Upto Q4 | |
|---|---|---|---|---|---|
| HMIS 9.9: Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly) | 2022-23 | 24.4 | 25.5 | ||
| HMIS 9.9: Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly) | 2021-22 | 19.3 | 20.7 | 21.2 | 21.9 |
| HMIS 9.9: Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly) | 2020-21 | 11.7 | 12.7 | 13.5 | 14.1 |
| HMIS 9.9: Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly) | 2019-20 | 11.1 | 12.6 | 14.0 | 14.9 |
| HMIS 9.9: Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly) | 2018-19 | 7.4 | 7.7 | 8.0 | 8.3 |
| HMIS 9.9: Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly) | 2017-18 | 5.5 | 5.9 | 6.2 | 6.6 |
| HMIS 9.1: Percentage of children 12-59 months provided Albendazole | 2022-23 | 4.3 | 5.8 | ||
| HMIS 9.1: Percentage of children 12-59 months provided Albendazole | 2021-22 | 2.0 | 4.8 | 4.6 | 4.5 |
| HMIS 9.1: Percentage of children 12-59 months provided Albendazole | 2020-21 | 0.4 | 2.7 | 3.1 | 3.6 |
| HMIS 9.1: Percentage of children 12-59 months provided Albendazole | 2019-20 | 0.7 | 3.1 | 2.5 | 2.9 |
| HMIS 9.1: Percentage of children 12-59 months provided Albendazole | 2018-19 | 1.1 | 2.4 | 1.8 | 2.3 |
| HMIS 9.1: Percentage of children 12-59 months provided Albendazole | 2017-18 | 0.5 | 2.0 | 1.5 | 2.1 |
Children 5-9 years| Year | Upto Q1 | Upto Q2 | Upto Q3 | Upto Q4 | |
|---|---|---|---|---|---|
| HMIS 23.1+23.3: Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school) | 2022-23 | 25.5 | 25.0 | ||
| HMIS 23.1+23.3: Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school) | 2021-22 | 19.1 | 21.3 | 22.4 | 23.1 |
| HMIS 23.1+23.3: Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school) | 2020-21 | 11.0 | 13.7 | 15.5 | 16.2 |
| HMIS 23.1+23.3: Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school) | 2019-20 | 24.5 | 27.7 | 29.9 | 30.1 |
| HMIS 23.1+23.3: Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school) | 2018-19 | 11.6 | 12.7 | 14.0 | 14.9 |
| HMIS 23.1+23.3: Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school) | 2017-18 | 8.6 | 9.2 | 9.1 | 8.8 |
| HMIS 23.2+23.4: Percentage of children (5-9 years) provided albendazole (In schools + out of school) | 2022-23 | 2.3 | 3.7 | ||
| HMIS 23.2+23.4: Percentage of children (5-9 years) provided albendazole (In schools + out of school) | 2021-22 | 1.8 | 3.7 | 3.3 | 3.5 |
| HMIS 23.2+23.4: Percentage of children (5-9 years) provided albendazole (In schools + out of school) | 2020-21 | 0.5 | 2.6 | 2.4 | 2.7 |
| HMIS 23.2+23.4: Percentage of children (5-9 years) provided albendazole (In schools + out of school) | 2019-20 | 1.5 | 5.3 | 4.4 | 4.8 |
| HMIS 23.2+23.4: Percentage of children (5-9 years) provided albendazole (In schools + out of school) | 2018-19 | 1.9 | 3.7 | 2.9 | 3.7 |
| HMIS 23.2+23.4: Percentage of children (5-9 years) provided albendazole (In schools + out of school) | 2017-18 | 1.0 | 2.8 | 2.1 | 2.4 |
Adolescents 10-19 years| Year | Upto Q1 | Upto Q2 | Upto Q3 | Upto Q4 | |
|---|---|---|---|---|---|
| HMIS 22.1.1: Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2022-23 | 42.5 | 41.7 | ||
| HMIS 22.1.1: Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2021-22 | 33.2 | 34.9 | 36.6 | 37.6 |
| HMIS 22.1.1: Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2020-21 | 12.6 | 16.6 | 19.0 | 20.9 |
| HMIS 22.1.1: Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2019-20 | 35.5 | 41.9 | 42.7 | 40.6 |
| HMIS 22.1.1: Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2018-19 | 26.7 | 27.8 | 28.3 | 28.0 |
| HMIS 22.1.1: Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2017-18 | 19.4 | 22.6 | 22.6 | 22.1 |
| HMIS 22.1.3: Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres | 2022-23 | 20.8 | 19.8 | ||
| HMIS 22.1.3: Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres | 2021-22 | 30.1 | 27.9 | 28.3 | 28.0 |
| HMIS 22.1.3: Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres | 2020-21 | 18.0 | 21.8 | 23.7 | 23.7 |
| HMIS 22.1.3: Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres | 2019-20 | 21.3 | 22.0 | 23.2 | 22.6 |
| HMIS 22.1.3: Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres | 2018-19 | 12.6 | 12.3 | 12.0 | 12.1 |
| HMIS 22.1.3: Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres | 2017-18 | 7.1 | 7.6 | 7.4 | 7.1 |
| HMIS 22.1.2: Percentage of (6-12 class) provided Albendazole in schools | 2022-23 | 4.1 | 6.2 | ||
| HMIS 22.1.2: Percentage of (6-12 class) provided Albendazole in schools | 2021-22 | 1.9 | 5.7 | 4.7 | 5.0 |
| HMIS 22.1.2: Percentage of (6-12 class) provided Albendazole in schools | 2020-21 | 1.6 | 4.5 | 4.5 | 4.5 |
| HMIS 22.1.2: Percentage of (6-12 class) provided Albendazole in schools | 2019-20 | 3.2 | 7.9 | 6.8 | 7.1 |
| HMIS 22.1.2: Percentage of (6-12 class) provided Albendazole in schools | 2018-19 | 2.2 | 5.7 | 4.7 | 5.6 |
| HMIS 22.1.2: Percentage of (6-12 class) provided Albendazole in schools | 2017-18 | 2.2 | 5.3 | 4.2 | 4.9 |
| HMIS 22.1.4: Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres | 2022-23 | 2.5 | 3.7 | ||
| HMIS 22.1.4: Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres | 2021-22 | 6.3 | 9.2 | 8.0 | 8.4 |
| HMIS 22.1.4: Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres | 2020-21 | 1.7 | 6.5 | 6.6 | 6.7 |
| HMIS 22.1.4: Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres | 2019-20 | 2.6 | 5.0 | 4.1 | 3.9 |
| HMIS 22.1.4: Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres | 2018-19 | 1.6 | 3.4 | 2.7 | 2.8 |
| HMIS 22.1.4: Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres | 2017-18 | 1.1 | 2.0 | 1.6 | 1.8 |
| HMIS 22.1.1.a: Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2022-23 | 42.9 | 42.1 | ||
| HMIS 22.1.1.a: Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2021-22 | 34.0 | 35.6 | 37.2 | 38.1 |
| HMIS 22.1.1.a: Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2020-21 | 12.8 | 16.7 | 19.3 | 21.3 |
| HMIS 22.1.1.a: Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2019-20 | 35.8 | 39.5 | 41.4 | 39.6 |
| HMIS 22.1.1.a: Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2018-19 | 27.0 | 28.9 | 29.4 | 29.1 |
| HMIS 22.1.1.a: Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2017-18 | 19.8 | 23.1 | 23.3 | 22.7 |
| HMIS 22.1.1.b: Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2022-23 | 42.0 | 41.3 | ||
| HMIS 22.1.1.b: Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2021-22 | 32.4 | 34.1 | 35.9 | 37.0 |
| HMIS 22.1.1.b: Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2020-21 | 12.3 | 16.4 | 18.7 | 20.4 |
| HMIS 22.1.1.b: Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2019-20 | 35.1 | 44.4 | 44.2 | 41.5 |
| HMIS 22.1.1.b: Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2018-19 | 26.1 | 26.4 | 26.9 | 26.6 |
| HMIS 22.1.1.b: Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools | 2017-18 | 19.0 | 22.0 | 22.0 | 21.4 |
| HMIS 22.1.2.a: Percentage of girls (6-12 class) provided Albendazole in schools | 2022-23 | 4.2 | 6.2 | ||
| HMIS 22.1.2.a: Percentage of girls (6-12 class) provided Albendazole in schools | 2021-22 | 1.9 | 5.6 | 4.7 | 4.9 |
| HMIS 22.1.2.a: Percentage of girls (6-12 class) provided Albendazole in schools | 2020-21 | 1.7 | 4.5 | 4.6 | 4.6 |
| HMIS 22.1.2.a: Percentage of girls (6-12 class) provided Albendazole in schools | 2019-20 | 3.3 | 7.7 | 6.8 | 7.2 |
| HMIS 22.1.2.a: Percentage of girls (6-12 class) provided Albendazole in schools | 2018-19 | 2.5 | 6.1 | 5.0 | 6.0 |
| HMIS 22.1.2.a: Percentage of girls (6-12 class) provided Albendazole in schools | 2017-18 | 2.3 | 5.5 | 4.3 | 5.1 |
| HMIS 22.1.2.b: Percentage of boys (6-12 class) provided Albendazole in schools | 2022-23 | 4.0 | 6.2 | ||
| HMIS 22.1.2.b: Percentage of boys (6-12 class) provided Albendazole in schools | 2021-22 | 1.9 | 5.8 | 4.8 | 5.0 |
| HMIS 22.1.2.b: Percentage of boys (6-12 class) provided Albendazole in schools | 2020-21 | 1.6 | 4.5 | 4.4 | 4.5 |
| HMIS 22.1.2.b: Percentage of boys (6-12 class) provided Albendazole in schools | 2019-20 | 3.1 | 8.0 | 6.8 | 7.0 |
| HMIS 22.1.2.b: Percentage of boys (6-12 class) provided Albendazole in schools | 2018-19 | 1.9 | 5.3 | 4.4 | 5.1 |
| HMIS 22.1.2.b: Percentage of boys (6-12 class) provided Albendazole in schools | 2017-18 | 2.1 | 5.1 | 4.1 | 4.7 |
Pregnant Women| Year | Upto Q1 | Upto Q2 | Upto Q3 | Upto Q4 | |
|---|---|---|---|---|---|
| HMIS 1.2.4: Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy) | 2022-23 | 92.6 | 94.6 | ||
| HMIS 1.2.4: Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy) | 2021-22 | 87.5 | 90.5 | 92.3 | 92.2 |
| HMIS 1.2.4: Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy) | 2021-22 | 74.2 | 82.1 | 81.5 | 83.6 |
| HMIS 1.2.4: Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy) | 2020-21 | 86.5 | 90.5 | 92.9 | 92.6 |
| HMIS 1.2.4: Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy) | 2019-20 | 87.5 | 89.3 | 90.3 | 90.8 |
| HMIS 1.2.4: Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy) | 2018-19 | 80.3 | 82.1 | 83.7 | 84.8 |
| HMIS 1.2.4: Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy) | 2017-18 | 70.7 | 73.5 | 76.1 | 77.3 |
| HMIS 1.2.6: Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester | 2022-23 | 58.8 | 60.1 | ||
| HMIS 1.2.6: Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester | 2021-22 | 46.2 | 49.4 | 49.1 | 50.2 |
| HMIS 1.2.6: Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester | 2021-22 | 54.4 | 54.5 | 55.6 | 55.4 |
| HMIS 1.2.6: Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester | 2020-21 | 47.1 | 48.3 | 49.1 | 49.0 |
| HMIS 1.2.6: Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester | 2019-20 | 40.6 | 42.1 | 43.0 | 43.7 |
| HMIS 1.2.6: Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester | 2018-19 | 35.2 | 36.0 | 37.1 | 37.5 |
| HMIS 1.2.6: Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester | 2017-18 | 24.8 | 26.9 | 28.3 | 29.3 |
| HMIS 1.4.2: Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9) | 2022-23 | 68.3 | 71.1 | ||
| HMIS 1.4.2: Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9) | 2021-22 | 62.9 | 65.6 | 67.4 | 66.9 |
| HMIS 1.4.2: Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9) | 2020-21 | 61.6 | 63.3 | 64.6 | 64.8 |
| HMIS 1.4.2: Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9) | 2019-20 | 68.7 | 70.8 | 71.4 | 71.1 |
| HMIS 1.4.2: Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9) | 2018-19 | 70.9 | 70.6 | 71.4 | 70.8 |
| HMIS 1.4.2: Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9) | 2017-18 | 62.9 | 65.4 | 66.7 | 66.4 |
| HMIS 1.4.3: Percentage of pregnant women (PW) having Hb level<7 (tested cases) | 2022-23 | 3.4 | 3.6 | ||
| HMIS 1.4.3: Percentage of pregnant women (PW) having Hb level<7 (tested cases) | 2021-22 | 2.8 | 3.0 | 3.1 | 3.1 |
| HMIS 1.4.3: Percentage of pregnant women (PW) having Hb level<7 (tested cases) | 2020-21 | 3.0 | 3.1 | 3.2 | 3.2 |
| HMIS 1.4.3: Percentage of pregnant women (PW) having Hb level<7 (tested cases) | 2019-20 | 3.5 | 3.7 | 3.7 | 3.7 |
| HMIS 1.4.3: Percentage of pregnant women (PW) having Hb level<7 (tested cases) | 2018-19 | 3.4 | 3.6 | 3.7 | 3.7 |
| HMIS 1.4.3: Percentage of pregnant women (PW) having Hb level<7 (tested cases) | 2017-18 | 3.2 | 3.5 | 3.6 | 3.6 |
| HMIS 1.4.4: Percentage of pregnant women (PW) having severe anemia (Hb<7) treated | 2022-23 | 2.2 | 2.4 | ||
| HMIS 1.4.4: Percentage of pregnant women (PW) having severe anemia (Hb<7) treated | 2021-22 | 1.8 | 2.0 | 2.1 | 2.0 |
| HMIS 1.4.4: Percentage of pregnant women (PW) having severe anemia (Hb<7) treated | 2020-21 | 1.8 | 1.9 | 1.9 | 1.9 |
| HMIS 1.4.4: Percentage of pregnant women (PW) having severe anemia (Hb<7) treated | 2019-20 | 2.2 | 2.3 | 2.3 | 2.2 |
| HMIS 1.4.4: Percentage of pregnant women (PW) having severe anemia (Hb<7) treated | 2018-19 | 1.8 | 1.9 | 2.0 | 2.0 |
| HMIS 1.4.4: Percentage of pregnant women (PW) having severe anemia (Hb<7) treated | 2017-18 | 1.4 | 1.6 | 1.7 | 1.6 |
Lactating Women 0-6 months| Year | Upto Q1 | Upto Q2 | Upto Q3 | Upto Q4 | |
|---|---|---|---|---|---|
| HMIS 6.3: Percentage of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery (Estimated Delivery) | 2022-23 | 52.1 | 95.0 | ||
| HMIS 6.3: Percentage of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery (Estimated Delivery) | 2021-22 | 45.2 | 51.1 | 54.2 | 54.6 |
| HMIS 6.3: Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery | 2020-21 | 41.9 | 47.9 | 51.5 | 51.8 |
| 2020-21 | 41.9 | 47.9 | 51.5 | 51.8 | |
| HMIS 6.3: Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery | 2019-20 | 41.9 | 46.6 | 49.1 | 49.8 |
| 2019-20 | 41.9 | 46.6 | 49.1 | 49.8 | |
| HMIS 6.3: Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery | 2018-19 | 35.4 | 39.0 | 40.9 | 41.6 |
| 2018-19 | 35.4 | 39.0 | 40.9 | 41.6 | |
| HMIS 6.3: Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery | 2017-18 | 26.9 | 31.4 | 33.9 | 34.6 |
| 2017-18 | 26.9 | 31.4 | 33.9 | 34.6 |
Stock Availability
Stocks Available| Year | Upto Q1 | Upto Q2 | Upto Q3 | Upto Q4 | |
|---|---|---|---|---|---|
| HMIS 19.9: Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric) | 2022-23 | 95.0 | 95.0 | ||
| HMIS 19.9: Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric) | 2021-22 | 95.0 | 95.0 | 95.0 | 95.0 |
| HMIS 19.9: Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric) | 2020-21 | 46.9 | 48.1 | 46.1 | 43.7 |
| HMIS 19.9: Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric) | 2019-20 | 53.6 | 50.9 | 52.1 | 52.4 |
| HMIS 19.9: Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric) | 2018-19 | 33.9 | 42.5 | 45.7 | 46.7 |
| HMIS 19.9: Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric) | 2017-18 | 31.9 | 28.1 | 30.3 | 35.0 |
| HMIS 19.6: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult) | 2022-23 | 23.3 | 95.0 | ||
| HMIS 19.6: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult) | 2021-22 | 40.6 | 40.5 | 39.7 | 40.1 |
| HMIS 19.6: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult) | 2021-22 | 40.6 | 40.5 | 39.7 | 40.1 |
| HMIS 19.6: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult) | 2021-22 | 28.0 | 27.9 | 27.4 | 27.6 |
| HMIS 19.6: Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult) | 2020-21 | 22.9 | 24.5 | 27.0 | 28.5 |
| 2020-21 | 22.9 | 24.5 | 27.0 | 28.5 | |
| HMIS 19.6: Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult) | 2019-20 | 32.0 | 33.6 | 33.2 | 30.7 |
| 2019-20 | 32.0 | 33.6 | 33.2 | 30.7 | |
| HMIS 19.6: Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult) | 2018-19 | 28.3 | 26.8 | 27.7 | 27.1 |
| 2018-19 | 28.3 | 26.8 | 27.7 | 27.1 | |
| HMIS 19.6: Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult) | 2017-18 | 15.1 | 21.4 | 22.4 | 23.3 |
| 2017-18 | 15.1 | 21.4 | 22.4 | 23.3 | |
| HMIS 19.7: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years) | 2022-23 | 72.2 | 64.0 | ||
| HMIS 19.7: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years) | 2021-22 | 61.9 | 61.0 | 58.8 | 61.6 |
| HMIS 19.7: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years) | 2020-21 | 42.5 | 46.8 | 46.8 | 45.0 |
| HMIS 19.7: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years) | 2019-20 | 49.9 | 53.5 | 53.4 | 51.3 |
| HMIS 19.7: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years) | 2018-19 | 54.0 | 51.1 | 48.3 | 45.0 |
| HMIS 19.7: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years) | 2017-18 | 41.8 | 35.6 | 33.0 | 35.7 |
| HMIS 19.8: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years) | 2022-23 | 57.2 | 51.5 | ||
| HMIS 19.8: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years) | 2021-22 | 54.8 | 52.5 | 51.0 | 50.9 |
| HMIS 19.8: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years) | 2020-21 | 51.3 | 68.1 | 66.7 | 62.1 |
| HMIS 19.8: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years) | 2019-20 | 68.0 | 67.7 | 65.5 | 62.7 |
| HMIS 19.8: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years) | 2018-19 | 61.1 | 51.0 | 48.5 | 51.3 |
| HMIS 19.8: Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years) | 2017-18 | 17.7 | 17.9 | 17.1 | 20.8 |
| HMIS 19.15: Number of stocks available for Albendazole tablets | 2020-21 | 48.7 | 63.3 | 75.6 | 77.7 |
| HMIS 19.15: Number of stocks available for Albendazole tablets | 2019-20 | 11.0 | 33.8 | 24.7 | 26.4 |
| HMIS 19.15: Number of stocks available for Albendazole tablets | 2019-20 | 95.0 | 95.0 | 84.1 | 74.7 |
| HMIS 19.15: Number of stocks available for Albendazole tablets | 2018-19 | 17.3 | 31.4 | 24.8 | 28.8 |
| HMIS 19.15: Number of stocks available for Albendazole tablets | 2018-19 | 81.9 | 81.0 | 77.6 | 78.5 |
| HMIS 19.15: Number of stocks available for Albendazole tablets | 2017-18 | 6.0 | 21.0 | 17.5 | 25.4 |
| HMIS 19.15: Number of stocks available for Albendazole tablets | 2017-18 | 27.7 | 31.6 | 35.6 | 43.9 |